Abstract :

Background: Chronic hepatitis B virus (HBV) infection remains a major global public-health problem and an important cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality. Although nucleos(t)ide analogue therapy has substantially improved management, antiviral resistance-associated mutations may occasionally be detected before treatment exposure.

Objective: To systematically determine the prevalence and distribution of established primary antiviral resistance-associated mutations among treatment-naïve patients with chronic HBV infection and to estimate the pooled prevalence of patients carrying at least one established primary resistance mutation.

Methods: A systematic review and meta-analysis were conducted using a patient-level endpoint defined as the presence of at least one established primary antiviral resistance-associated mutation in a unique treatment-naïve patient. Secondary or compensatory mutations were not counted as primary resistance when occurring alone. Studies using highly sensitive assays, including mutation-specific PCR and next-generation sequencing, were considered separately where appropriate. The review was structured according to PRISMA 2020.

Results: The current primary quantitative dataset comprised 42 cohorts involving 9,811 evaluable treatment-naïve participants, of whom 417 carried at least one qualifying primary resistance-associated mutation, giving a crude prevalence of 4.25%. The current random-effects synthesis estimated an overall pooled prevalence of 1.80% (95% CI, 1.04–3.09%). Between-study heterogeneity was very high (I²=93.3%; τ²=2.541; Q=616.02). The approximate 95% prediction interval was 0.08–30.41%.

Conclusion: Naturally occurring primary antiviral resistance-associated mutations are detectable in a minority of treatment-naïve patients with chronic HBV infection, but reported prevalence varies substantially according to population, geography, genotype, study design, and assay sensitivity. The pooled estimate should therefore not be interpreted as a universal prevalence applicable to every clinical setting.

---

Keywords :

antiviral resistance, Chronic Hepatitis B, hepatitis B virus, resistance-associated mutations, reverse transcriptase, treatment-naïve.

---

References :

1. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization. 2024
2. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2025;83(2):502–583. https://doi.org/10.1016/j.jhep.2025.03.018
3. Qian F, Zou W, Qin J, Li D. Naturally occurring genotypic drug-resistant mutations of HBV in Huzhou, China: a single-center study. Infect Drug Resist. 2017;10:507-509. doi:10.2147/IDR.S149992. PMID:29276396.
4. Zhu B, Wang T, Wei X, Zhuo Y, Liu A, Zhang G. Accumulation of mutations in reverse transcriptase of hepatitis B virus is associated with liver disease severity in treatment-naïve Chinese patients with chronic hepatitis B. Adv Clin Exp Med. 2017;26(7):1123-1129. doi:10.17219/acem/63998. PMID:29211361.
5. Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology. 2012;55(1):36-44. doi:10.1159/000323521. PMID:21311172.
6. Locarnini, S., & Mason, W. S. Cellular and virological mechanisms of HBV drug resistance. Journal of Hepatology. 2006;44(2):422–431.
7. Locarnini, S., & Zoulim, F. Molecular genetics of HBV infection. Antiviral Therapy. 2016;21(7), 1–12.
8. Choi, Y. M., Lee, S. Y., & Kim, B. J. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World Journal of Gastroenterology. 2018:24(16), 1708–1724. https://doi.org/10.3748/wjg.v24.i16.1708
9. Zhang, Q., Cao, F., & Zhang, W. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2015;30(10), 1529–1538. https://doi.org/10.1111/jgh.12831
10. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., Stewart, L. A., Thomas, J., Tricco, A. C., Welch, V. A., Whiting, P., & Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372, n71. https://doi.org/10.1136/bmj.n71
11. Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., Koffel, J. B., & PRISMA-S Group. PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. Systematic Reviews. 2021;10, 39.
12. Lumley, S. F., Delphin, M., Mokaya, J. F., Tan, C. S. C., Martyn, E., Anderson, M., Li, K. C., Waddilove, E., Sukali, G., Downs, L. O., Said, K., Okanda, D., Campbell, C., Harriss, E., Shimakawa, Y., & Matthews, P. C. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir. Journal of Clinical Virology.2024;174, 105711. https://doi.org/10.1016/j.jcv.2024.105711
13. Hoang MC, Duong HQ, Le VD, Nguyen TTN, Ngo VL, Dang TH. Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment-naïve patients with chronic hepatitis B in Bac Ninh, Vietnam: a cross-sectional study. Ther Adv Infect Dis. 2025;12:20499361251344784. doi:10.1177/20499361251344784. PMID:40529960.